Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial

CONCLUSIONS AND RELEVANCE: The findings of this trial suggest that heat shock protein 90 inhibition by RGRN-305 offers a novel mechanism of action in treating hidradenitis suppurativa, warranting further evaluation in larger trials.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05286567.PMID:38055242 | DOI:10.1001/jamadermatol.2023.4800
Source: Pain Physician - Category: Anesthesiology Authors: Source Type: research